Just days after his arrest, pharmaceutical executive Martin Shkreli is back in a familiar place: on the offensive.

In his first interview since he was charged on December 17 for allegedly misleading investors in his hedge funds and raiding a public company to cover the losses, Shkreli told The Wall Street Journal he had been targeted by authorities for his much-criticised drug-price hikes and over-the-top public persona.